Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Liver Immunosuppression Free Trial
NCT02498977 · King's College London · PHASE4 · terminated · last registry update 2024-03-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Primary endpoint not reached.” | – | Registry record, King's College London |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FKBP1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-05Results posted on the registry: Abramson Cancer Center at Penn Medicine, Hydroxychloroquine + Everolimus (NCT03032406)
- 2025-02-12Phase 3 first posted: Incyte Corporation, INCA034176 + Best Available Therapy (BAT) (NCT06821542)
- 2025-02-11Results posted on the registry: National Cancer Institute (NCI), Sapanisertib (NCT03047213)
- 2024-11-29Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Alemtuzumab + Sirolimus (NCT02105766)
- 2024-11-08Phase 3 first posted: Jiangsu Simcere Pharmaceutical Co., Ltd., SIM0270 + Everolimus (Afinitor®) (NCT06680921)
- 2024-10-09Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), lulizumab pegol + antithymocyte globulin (rabbit) (NCT04066114)
- 2024-10-09Results posted on the registry: Weill Medical College of Cornell University, Fludarabine + Melphalan (NCT01810588)
- 2024-10-08Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Polyclonal Regulatory T Cells + Everolimus (NCT02711826)
- 2024-10-01Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Dactinomycin (NCT02567435)
- 2024-09-26Phase 3 first posted: Incyte Corporation, Tacrolimus (Tac) + Methotrexate (MTX) (NCT06615050)
- 2024-07-23Results posted on the registry: Dartmouth-Hitchcock Medical Center, Cyclophosphamide + Fludarabine (NCT03480360)
- 2024-04-24Phase 3 first posted: MedSIR, Everolimus + Elacestrant (NCT06382948)
- 2024-03-04Phase 3 first posted: University Hospital, Rouen, Conversion to Belatacep + Standard of care treatment (SOC regimen) with Tacrolimus (NCT06291103)
- 2024-02-29Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Alemtuzumab + Sirolimus (NCT00061568)
- 2024-02-05Phase 3 first posted: Sanofi, Amlitelimab + Placebo (NCT06241118)
- 2024-02-01Phase 3 first posted: Nantes University Hospital, TACROLIMUS (NCT06235892)
- 2023-12-20Results posted on the registry: SWOG Cancer Research Network, anastrozole + everolimus (NCT01674140)
- 2023-09-13Results posted on the registry: City of Hope Medical Center, Fludarabine + Itacitinib Adipate (NCT04339101)
- 2023-06-27Results posted on the registry: National Cancer Institute (NCI), Ipilimumab + Nivolumab (NCT03816332)
- 2023-05-10Results posted on the registry: City of Hope Medical Center, busulfan + cyclophosphamide (NCT00544115)
- 2023-04-04Results posted on the registry: City of Hope Medical Center, clofarabine + melphalan (NCT01885689)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision